Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension
Autor: | Eric E. Lloyd, Keith C. Ferdinand, Michael A. Weber, Jingtao Wu, William C. Cushman, George L. Bakris, William B. White |
---|---|
Rok vydání: | 2018 |
Předmět: |
Male
medicine.medical_specialty Angiotensin receptor Urology Tetrazoles 030204 cardiovascular system & hematology Placebo White People 03 medical and health sciences 0302 clinical medicine Hydrochlorothiazide Internal medicine medicine Humans 030212 general & internal medicine Azilsartan Medoxomil Antihypertensive Agents Aged Oxadiazoles Dose-Response Relationship Drug business.industry Imidazoles Chlorthalidone Middle Aged United States Black or African American Drug Combinations Blood pressure Hypertension Ambulatory Cardiology Benzimidazoles Female Cardiology and Cardiovascular Medicine business Olmesartan Angiotensin II Type 1 Receptor Blockers medicine.drug |
Zdroj: | The American Journal of Cardiology. 122:1496-1505 |
ISSN: | 0002-9149 |
DOI: | 10.1016/j.amjcard.2018.07.022 |
Popis: | Two post hoc analyses in self-identified black and white patients with hypertension evaluated the angiotensin II receptor blocker azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ). One analysis pooled 1,610 patients from two 6-week randomized controlled trials to compare once daily AZL-M 40 mg, AZL-M 80 mg, OLM 40 mg, and placebo. The second analysis included 1,020 patients from a 12-week randomized controlled trial to compare once daily AZL-M/CLD 40/25 mg, AZL-M/CLD 80/25 mg, and OLM/HCTZ 40/25 mg. Efficacy end points were 24-hour mean ambulatory and clinic systolic and diastolic blood pressure (SPB/DBP) and the percentage of patients achieving clinic SBP/DBP targets. Treatment with AZL-M 80 mg lowered mean clinic SBP by 12.5 mm Hg (p |
Databáze: | OpenAIRE |
Externí odkaz: |